LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Wednesday that it now expects to complete its three-part transaction with Novartis AG (NOVN.VX) in the week commencing March 2, following good progress on obtaining clearances and regulatory approvals.

The three-part transaction with Novartis includes Glaxo's acquisition of Novartis's vaccines business, the creation of a consumer healthcare joint venture and the divestment to Novartis of GlaxoS's Oncology portfolio.

Shares of GlaxoS at 1628 GMT trading 0.1% lower at 1,545 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.